Business Context and Reporting Period
This Form 8-K Current Report was filed by EyePoint Pharmaceuticals, Inc. on January 10, 2022. The filing discloses the appointment of a new senior executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer, effective January 10, 2022. This appointment includes the following compensation components:
- Base Salary: $420,000 annually.
- Sign-On Bonus: $108,000 total, payable in two tranches of $54,000. The bonus is subject to forfeiture if employment is terminated voluntarily without good cause or for cause within the first 15 months.
- Equity Grant: Options to purchase 100,000 shares of common stock at an exercise price of $12.62 per share. Vesting begins at 25% on the first anniversary, followed by monthly vesting through the fourth anniversary.
- Annual Bonus: Target of 45% of base salary, based on individual and corporate performance objectives.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. Regarding risks and contingencies, the employment agreement includes standard provisions for termination payments:
- Termination without Cause/Good Cause: Entitles Mr. Pine to 12 months of base salary, 100% of the target bonus, and health premium reimbursements.
- Change of Control: Triggers immediate full vesting of unvested equity awards if Mr. Pine remains employed on the date of the event.
Investor Verification Checklist
- Verify the impact of the new executive's compensation package on the company's cash burn rate and future equity dilution.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good cause."
- Confirm the status of the 100,000 share option grant and its treatment under Nasdaq Listing Rule 5635(c)(4).
- Assess Mr. Pine's prior experience at Medexus, Lupin, and Novartis relative to EyePoint's current strategic needs.